The Journal
Our latest research, findings and articles on type 2 diabetes, weight management and health.
News
Press Release: Professor Sir Jonathan Van-Tam joins Reset Health
Professor Sir Jonathan brings extensive experience in public health, government, academia, and the pharmaceutical industry.
From costly to cost-effective: rethinking commissioning of anti-obesity medications
Bringing together industry-leading digital weight management support with the world's leading clinical research and healthcare data company to deliver a sustainable and effective weight management service.
Reset Health welcomes Rochelle Morris as Chief Product Officer
Rochelle brings over 20 years of leadership experience in healthcare, spanning clinical innovation, digital transformation, and strategic product development.
Reset Health welcomes David Plans as Chief Scientific Officer
We’re delighted to welcome David Plans who has joined Reset Health as Chief Scientific Officer (CSO).
Obesity in the NHS – A Call to Action for a Healthier Future
Obesity is a growing problem in the UK, affecting more and more people and putting a strain on both individuals and the healthcare system
Reset Health announces the appointment of Sarah Le Brocq as UK Head of Public Affairs
Reset Health is pleased to announce the appointment of Sarah Le Brocq as its new UK Head of Public Affairs, effective immediately.
Published Data
Clinical Outcomes: How the Roczen Programme Improves Eating Habits, Mood, and Quality of Life
New peer-reviewed research published in Eating Behaviours via ScienceDirect highlights how the Roczen Programme, a clinically supported, digitally delivered weight management programme using time-restricted eating, led to significant improvements in eating behaviours, symptoms of depression, and quality of life over 24 weeks.
Obesity Update 2024: The impact of Roczen in an ethnically diverse population in the UK
We conducted a retrospective, real-world service evaluation. Patients were initiated on a 16-hour TRE plan with low-carbohydrate, moderate- protein dietary guidance.
ECO 2023: The Impact of Roczen Programmes on Glycaemic Control
EASO 2023: The Roczen Programme - A digitally-enabled, medically-led intervention for obesity and T2DM: outcomes at 1 year
ICE 2022: Service evaluation of a real-world, digitally enabled time restricted eating programme for adults in the UK
The aim of this service evaluation was to assess the impact of the Reset Health programme on weight, metabolic parameters, and other health-related outcomes at 12 and 24 weeks.
Lifestyle
Workplace
The hidden cost of obesity in the workplace
Obesity is a global public health concern that affects not only those living with the condition, but also workplace productivity, company culture and employee wellbeing.
Medication
Doctors explain everything you need to know about the latest obesity medications
You may know them as weight-loss injections, gut hormone medications, incretin-based therapies, GLP-1/GIP, GLP-1, semaglutide, tirzepatide, Wegovy, Mounjaro or Ozempic. These new obesity medications have been making waves in the mainstream media for their potential to help people manage their weight more effectively. With a hive of misinformation already out there, our in-house experts, Dr. Laura Falvey and Dr. Claudia Ashton, are here to give you the facts about these specialist medications. They will cover what they are, how they work, who they’re for, common side effects and much more.
Lifestyle
Workplace
The hidden cost of obesity in the workplace
Obesity is a global public health concern that affects not only those living with the condition, but also workplace productivity, company culture and employee wellbeing.
Clinical Outcomes
Clinical Outcomes: How the Roczen Programme Improves Eating Habits, Mood, and Quality of Life
New peer-reviewed research published in Eating Behaviours via ScienceDirect highlights how the Roczen Programme, a clinically supported, digitally delivered weight management programme using time-restricted eating, led to significant improvements in eating behaviours, symptoms of depression, and quality of life over 24 weeks.
Obesity Update 2024: The impact of Roczen in an ethnically diverse population in the UK
We conducted a retrospective, real-world service evaluation. Patients were initiated on a 16-hour TRE plan with low-carbohydrate, moderate- protein dietary guidance.
ECO 2023: The Impact of Roczen Programmes on Glycaemic Control
EASO 2023: The Roczen Programme - A digitally-enabled, medically-led intervention for obesity and T2DM: outcomes at 1 year
ICE 2022: Service evaluation of a real-world, digitally enabled time restricted eating programme for adults in the UK
The aim of this service evaluation was to assess the impact of the Reset Health programme on weight, metabolic parameters, and other health-related outcomes at 12 and 24 weeks.
News & PR
Press Release: Professor Sir Jonathan Van-Tam joins Reset Health
Professor Sir Jonathan brings extensive experience in public health, government, academia, and the pharmaceutical industry.
From costly to cost-effective: rethinking commissioning of anti-obesity medications
Bringing together industry-leading digital weight management support with the world's leading clinical research and healthcare data company to deliver a sustainable and effective weight management service.
Reset Health welcomes Rochelle Morris as Chief Product Officer
Rochelle brings over 20 years of leadership experience in healthcare, spanning clinical innovation, digital transformation, and strategic product development.
Reset Health welcomes David Plans as Chief Scientific Officer
We’re delighted to welcome David Plans who has joined Reset Health as Chief Scientific Officer (CSO).
Obesity in the NHS – A Call to Action for a Healthier Future
Obesity is a growing problem in the UK, affecting more and more people and putting a strain on both individuals and the healthcare system
Reset Health announces the appointment of Sarah Le Brocq as UK Head of Public Affairs
Reset Health is pleased to announce the appointment of Sarah Le Brocq as its new UK Head of Public Affairs, effective immediately.
Reset Health partners with Affidea to launch Roczen to millions across Europe
The Roczen platform from Reset Health will support Affidea’s 14 million patients by providing personalised care and GLP-1 medications to improve health outcomes.
Medication
Doctors explain everything you need to know about the latest obesity medications
You may know them as weight-loss injections, gut hormone medications, incretin-based therapies, GLP-1/GIP, GLP-1, semaglutide, tirzepatide, Wegovy, Mounjaro or Ozempic. These new obesity medications have been making waves in the mainstream media for their potential to help people manage their weight more effectively. With a hive of misinformation already out there, our in-house experts, Dr. Laura Falvey and Dr. Claudia Ashton, are here to give you the facts about these specialist medications. They will cover what they are, how they work, who they’re for, common side effects and much more.
starting with Type 2 diabetes and obesity.
